Clinical trials: Vaccine Prophylaxis
COVID-19
Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19
This is a randomized, double-blinded, phase ⅠV clinical trial of SARS-CoV-2 inactivated vaccine manufactured by manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05079217
- Testing
- High-dosage SARS-CoV-2 vaccine, Medium-dosage SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza, Human, Influenza, Human Prevention
Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
This is a randomized, blinded, active-controlled phase III clinical trial to evaluate the immunogenicity and safety of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above).
- Conditions
- Influenza, Human, Influenza, Human Prevention, Influenza a, Influenza B
- Trial name
- NCT06800950
- Testing
- QIV, QIV Control
- Where
- 3 sites in China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
SARS-CoV-2 Infection
PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19
The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the SpFN COVID-19 vaccine with Army Liposomal Formulation QS21 (ALFQ) adjuvant in healthy adults ages 18-55.
- Trial name
- NCT04784767
- Testing
- 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Influenza
Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control of a pandemic will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00309647
- Testing
- Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine, Influenza Monovalent Whole virus (H5N1)
- Where
- 9 sites in Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine
This is a single blind, reference drug controlled, one center viral immunogenicity and tolerability study of FluvalAB FL-K-004 Trivalent Influenza Vaccine with 6 μg HA/strain/dos antigen content to assess immunogenicity and…
- Trial name
- NCT00778297
- Testing
- Vaccination with FluvalAB FL-K-004 trivalent flu vaccine, Vaccination with FluvalAB trivalent influenza vaccine
- Where
- Hungary
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Prophylaxis of Avian Influenza
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years
Evaluate the immune response and reactogenicity of H5N1 vaccination in subjects aged 6 months to 17 years compared to seasonal flu vaccination
- Trial name
- NCT00537524
- Testing
- H5N1 Influenza Vaccine
- Where
- Finland
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
Background: HIV stands for human immunodeficiency virus, which is the virus that causes AIDS. There is currently no licensed vaccine to prevent HIV infection.
- Trial name
- NCT03783130
- Testing
- VRC-HIVRGP096-00-VP, Alum Adjuvant
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Papilloma Virus
Marketability of a Technology-based Intervention to Increase HPV Vaccination
The overall goal of this SBIR Phase II project is to reduce cancer rates by marketing a brief, easily implemented technology-based intervention that increases human papillomavirus (HPV) vaccination among Planned Parenthood and…
- Trial name
- NCT03497936
- Testing
- Women's Stories
- Where
- 7 sites in United States
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Real Prevention, LLC
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00831012
- Testing
- rDEN3delta30/31-7164
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infections, Rotavirus
Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis
Rotavirus (RV) is the most important cause of acute gastroenteritis (GE) requiring the hospitalization of infants and young children in developed and developing countries and can be a frequent cause of death in children less than…
- Trial name
- NCT00137930
- Testing
- Live attenuated rotavirus vaccine
- Where
- 5 sites in Finland
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Virus Diseases
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)
Avian influenza (AI), also known as bird flu, has become a major public health concern in many regions of the world. The purpose of this study is to evaluate the safety of and immune response to an AI vaccine in healthy adults.
- Trial name
- NCT00380237
- Testing
- H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cervical Cancer, Precancerous Condition
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in…
- Trial name
- NCT00128661
- Testing
- human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, hepatitis A inactivated virus vaccine
- Where
- Costa Rica
- Volunteers
- 7,466 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
Seasonal Influenza Preventative Vaccine Pharmacodynamics
Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
This is a phase 1 open-label pharmacodynamics study in healthy adults. The purpose of the study is to determine if the tablet formulation size of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, has an impact on…
- Trial name
- NCT03121339
- Testing
- VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Vaxart
Influenza
Intradermal Influenza Vaccine Study in Elders
This randomized trial compared the immunogenicity of 60% dose intradermal (ID) influenza vaccination to standard intramuscular (IM) vaccination of full-dose or 60% dose vaccine.
- Trial name
- NCT00504231
- Testing
- Fluzone Influenza Vaccine (2007-2008)
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- PATH
Prevention of Meningococcal Infection
Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine
Persistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine
- Trial name
- NCT00310713
- Testing
- Meningococcal C conjugate vaccine
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Chronic Lymphocytic Leukemia, COVID-19 Infection
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
This phase II trial compares the effect of the GEO-CM04S1 vaccine with the current standard of care vaccine in preventing COVID-19 infections in patients with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT05672355
- Testing
- Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- City of Hope Medical Center
Influenza, Virus Diseases
Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults
Over the past decade, avian influenza (AI) has become a major health concern. The development of safe and effective vaccines against avian strains infecting people is important.
- Trial name
- NCT00516035
- Testing
- Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study
The goal is to demonstrate the immunogenicity and safety of Zostavax® in HIV positive individuals. Study participants are stratified into different patient groups according to their CD4 cell count, viral load and HIV Status.
- Trial name
- NCT01213810
- Testing
- Zostavax
- Sponsor
- University of Zurich
Rotavirus Infection
Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection
This study is a randomized, double-blinded, placebo-controlled, Phase 1, dose-escalation study to evaluate the safety, reactogenicity and immunogenicity of Inactivated Rotavirus Vaccine (IRV) performed in healthy adult (aged…
- Trial name
- NCT04626856
- Testing
- Low dosage IRV on a 0- and 28-day schedule, Medium dosage IRV on a 0- and 28-day schedule, High dosage IRV on a 0- and 28-day schedule
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences